Investigates the impact of semaglutide on oral microbiota and host gene expression in diabetic mice, suggesting significant metabolic changes.
Type 2 diabetes (T2D) is associated with alterations in the oral microenvironment, including microbial dysbiosis and host transcriptional changes. Whether antidiabetic therapies such as semaglutide modulate these alterations in a coordinated manner remains unclear.To investigate the association between semaglutide treatment and coordinated changes in oral microbiota and host transcriptional programs.16S rRNA sequencing and bulk RNA-seq were performed on oral samples from WT, db/db, and semaglutide-treated db/db mice. Microbial diversity, taxonomic composition, gene expression, and integrative analyses were conducted. β diversity revealed clear separation between WT and db/db groups, with treated samples partially shifting toward the WT state, while α diversity showed no significant difference. The dysbiosis index was increased in db/db mice and reduced following treatment. At the genus level, Bacillus and Delftia decreased, whereas Streptococcus increased in db/db mice, with opposite trends after treatment. Transcriptomic analysis identified interferon-enriched and metabolic-associated gene clusters, with modulation of interferon- and antiviral-response pathways following treatment. Integration analyses demonstrated reorganization of gene-microbiota networks and significant correlations between cluster-specific transcriptional programs and dysbiosis.T2D is associated with coordinated alterations in oral microbiota and host transcription, and semaglutide treatment is accompanied by partial remodeling of these features.
No takes yet. Share an insight, caveat, or question.
Ying et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: